CD8A and neoplasm: Mechanistically, neoadjuvant therapy proves particularly beneficial for patients with MIBC who possess pre-existing circulating Tfh cells, as these cells play a pivotal role in orchestrating the development and maturation of tertiary lymphoid structures (TLS) like cells and in promoting the infiltration of CD8+ T cells into the tumor microenvironment (10).